Skip to main content Skip to main content
Go to homepage

Sucraid® Oral Solution to treat CSID

Sucraid® Oral Solution to treat Congenital Sucrase-Isomaltase Deficiency (CSID)


For complete details, please visit this study on

Interested in participating?
We are currently recruiting
Study Sponsor:

QOL Medical, LLC

Full IRB Study Title:
Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Joann Katz: 330-543-0690

Lead Investigator
Kevin Watson, MD, FAAP

Pediatric Gastroenterologist; Assistant Director, Clinical Informatics, Specialty Systems; Medical Director, Therapy Plans
Pediatric Gastroenterology

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.